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Abstract
The low molecular weight protein tyrosine phosphatase (LMPTP), encoded by the ACP1 gene, is a ubiquitously
expressed phosphatase whose in vivo function in the heart and in cardiac diseases remains unknown. To investigate
the in vivo role of LMPTP in cardiac function, we generated mice with genetic inactivation of the Acp1 locus and
studied their response to long-term pressure overload. Acp1−/− mice develop normally and ageing mice do not
show pathology in major tissues under basal conditions. However, Acp1−/− mice are strikingly resistant to pressure
overload hypertrophy and heart failure. Lmptp expression is high in the embryonic mouse heart, decreased in the
postnatal stage, and increased in the adult mouse failing heart. We also show that LMPTP expression increases in
end-stage heart failure in humans. Consistent with their protected phenotype, Acp1−/− mice subjected to pressure
overload hypertrophy have attenuated fibrosis and decreased expression of fibrotic genes. Transcriptional profiling
and analysis of molecular signalling show that the resistance of Acp1−/− mice to pathological cardiac stress
correlates with marginal re-expression of fetal cardiac genes, increased insulin receptor beta phosphorylation, as
well as PKA and ephrin receptor expression, and inactivation of the CaMKII𝛅 pathway. Our data show that ablation
of Lmptp inhibits pathological cardiac remodelling and suggest that inhibition of LMPTP may be of therapeutic
relevance for the treatment of human heart failure.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Cardiovascular diseases remain the leading cause of
mortality worldwide, with heart failure being the fastest
growing condition in the past decade. Heart failure com-
plicates a number of common conditions (ie hyperten-
sion, myocardial infarction, and cardiomyopathies) and
is associated with a phase of cardiac hypertrophy that
is initially beneficial, but that often progresses to heart
failure if the stress stimulus is not alleviated [1].
Numerous studies have implicated protein kinases
in the pathogenesis of heart failure [1]. On the other
hand, fewer studies have addressed the role of protein
phosphatases in cardiac pathologies. While several ser-
ine/threonine phosphatases play a role in heart diseases
[2–5], only three members of the protein tyrosine phos-
phatases (PTPs) [6] (ie the protein tyrosine phosphatase,
non-receptor type 11, PTPN11; the phosphatase and
tensin homologue, PTEN; and the protein tyrosine phos-
phatase 1B, PTP1B) have been implicated in cardiac
abnormalities [7–9]. The low molecular weight protein
tyrosine phosphatase (LMPTP) is another PTP highly
expressed in the heart [10]. However, its function in heart
pathophysiology remains unknown. Encoded by the
ACP1 gene, LMPTP is an 18 kDa cytosolic enzyme with
a wide tissue distribution [11]. As a result of alternative
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mRNA splicing, two active isoforms are generated,
called ACP1-F or -S and LMPTP-A or -B in humans
and IF1 and IF2 in rodents [12–14]. A second IF2 iso-
form called IF2p not encoded by Acp1 and derived from
a pseudogene has also been reported, although its molec-
ular function remains undetermined [11].
Genetic association studies have suggested a role
for ACP1 in human cardiovascular disorders [12–15].
LMPTP appears to modulate signalling through several
tyrosine kinase receptors [16–20]. Analysis of liver and
fat tissue from mice injected with anti-Lmptp antisense
oligonucleotides suggested that Lmptp acts as a neg-
ative regulator of insulin signalling [21]. However, a
mouse model of Lmptp deficiency is still lacking and
the functional role of Lmptp in cardiac diseases remains
unknown.
In the present study, we show that LMPTP expres-
sion increases in end-stage heart failure in mice and
in humans and we addressed the function of Lmptp in
heart failure by generating and characterizing the first
mouse model carrying inactivation of the Acp1 gene.
Acp1−/− mice subjected to chronic cardiac stress dis-
play strikingly preserved contractile function and atten-
uated histological and molecular evidence of cardiac
fibrosis. This phenotype correlates with limited reacti-
vation of the fetal gene programme. In addition, hearts
from Acp1−/− mice show increased phosphorylation of
the insulin receptor (IR), and enhanced expression of
molecules involved in protective signalling and attenua-
tion of signalling pathways with deleterious effects.
Materials and methods
Details of themethods and antibodies are provided in the
Supplementary materials and methods.
Generation of Acp1 knockout mice
Acp1 gene-trapped mice were generated according
to Stryke et al [22]. Acp1 knockout (KO) mice were
backcrossed for at least ten generations onto the Balb/c
background. Male Balb/c and Acp1 KO mice 13–15
weeks old were subject to trans-aortic constriction
(TAC) as previously described [23]. Sham operations
were performed by opening and closing the chest.
The Vevo 770 (VisualSonics, Toronto, Canada) and
Vivid E9 (GE Healthcare, Little Chalfont, Bucks, UK)
high-resolution In-Vivo Imaging systems were used to
measure cardiac dimension and function in mice. Before
assessing cardiac functional parameters, mice were sub-
jected to 1–2% isoflurane. At the study end-point, hearts
were collected after opening the pericardial cavity and
immediately placed in liquid nitrogen or retro-perfused
to generate paraffin-embedded sections.
Immunofluorescence
At the study end-point, paraffin-embedded heart
sections were deparaffinized and after antigen retrieval
in citrate buffer and blocking, wheat germ agglutinin
antibody was incubated overnight at 4 ∘C. After wash-
ing, secondary antibody incubation was performed for
2 h. Cells were then washed and slides were mounted
and visualized using a 20× objective and a Zeiss (Axio
Imager) microscope. Cell surface areas were measured
using a tool in NIS Element software that created
regions of interest. Surface areas were calculated from
100 cells from three separate areas in three animals
from each group of mice.
Primary neonatal rat cardiomyocytes
Primary neonatal rat cardiomyocytes were isolated
using the Worthington Neonatal Cardiomyocytes Sys-
tem (Worthington Biochemical Corp, Lakewood, NJ,
USA) according to the manufacturer’s instructions.
Protein extraction, immunoblotting,
and co-immunoprecipitation
Whole heart extracts resuspended in a high salt lysis
buffer containing a cocktail of protease and phosphatase
inhibitors were prepared. Forty micrograms of heart
extract was analysed by immunoblot. Whole heart
extracts were immunoprecipitated using anti-insulin
receptor β antibody according to the manufacturer’s
instructions (Pierce Classic IP kit; Pierce Thermosci-
entific, Grand Island, NY, USA). Immunoprecipitated
samples (30 μl) were analysed by immunoblotting using
anti-pTyr antibody. The membrane was then stripped
and incubated with anti-IRβ antibody.
Q-PCR
Total RNA was extracted from mouse hearts using
RNAEasy (Qiagen, Maryland, USA) according to the
manufacturer’s protocol. cDNA was synthesized using
Superscript III (Invitrogen) using random hexamers.
PCR reactions were run using 10 ng of cDNA and
primers were added in PCR buffer IQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA, USA).
The primers used for fetal cardiac genes, PLN, and
SERCA2A are listed in the Supplementarymaterials and
methods.
Array hybridization and microarray analysis
Total RNA was isolated from heart tissues using stan-
dard protocols. Sample handling, cDNA synthesis,
cRNA labelling and synthesis, hybridization, washing,
array (GeneChip® Mouse Genome 430 2.0 Array;
Affymetrix Inc, Santa Clara, CA, USA) scanning, and
all related quality controls were performed according
to the manufacturer’s instructions. The open source
R/Bioconductor packages [24] were used for processing
and analysis of microarray data. Significantly modu-
lated genes were defined as those with absolute fold
change (FC) greater than 1.5 and unadjusted p value less
than 0.05. Statistical analyses were performed by using
ANOVA, SAS 9.2 (SAS Institute, Cary, NC, USA),
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MATLAB software packages (Mathworks, Natick, MA,
USA), and PARTEK Genomics Suite (Partek Inc, St
Louis, MO, USA). Microarray data are provided in the
Supporting information.
Human subjects
All procedures were performed under approved pro-
tocol (RAC# 2100 023) from the Institutional Review
Board at King Faisal Specialist Hospital and Research
Centre. Patients with end-stage heart failure secondary
to idiopathic dilated cardiomyopathy were followed at
King Faisal Heart Centre and were enrolled in our study
after informed consent. After transplantation, cardiomy-
opathic hearts were collected and stored at −80 ∘C for
further biochemical analysis. Normal human hearts were
obtained from donors who died from accidental death or
from causes other than cardiac diseases and that could
not be transplanted because of incompatibility with the
recipient.
Dissection and histological analyses of human
and mouse hearts
Samples from the same region of the left ventricle
were dissected from normal and cardiomyopathic hearts.
Total proteins were prepared after grinding of the tis-
sue as described above. After fixation in formalin and
embedding in paraffin, heart sections were stained with
Masson’s trichrome using standard procedures.
Statistical analysis
For echocardiographic data, statistical analysis was per-
formed using Prism 5 software. Data were analysed
using repeated measures two-way ANOVA followed by
a Bonferroni post-hoc test. For all other data analyses,
Student’s t-test was performed. Graphical data are repre-
sented as the mean±SEM. p values less than 0.05 were
considered statistically significant.
Results
Developmental regulation of Lmptp in rodent heart
LMPTP is a cytosolic enzyme initially purified as
a major PTP in bovine heart [10]. As expected, we
found that Lmptp is highly expressed in adult BALB/c
mouse heart and is detected as two bands of molecular
mass near 18 kDa (Figure 1A). Immunofluorescence
of adult rodent cardiac sections showed high levels of
Lmptp in the sarcolemmal membrane and lower levels
in the myocardium (Figure 1B and Supplementary
Figure 1A). Lmptp was also detected in neonatal rat
ventricular myocytes (Supplementary Figure 1B). Next,
we investigated if Lmptp expression is developmentally
regulated. Lmptp protein was high at embryonic days
11.5 and 15, declined between embryonic days 15 and
19, and remained similar between postnatal days 1 and
7 and in young adulthood (Figures 1C and 1D). These
results show that Lmptp is highly expressed during
early embryonic development and is expressed in the
adult heart.
LMPTP is up-regulated in failing human and rodent
hearts
Many embryonic genes are up-regulated in heart fail-
ure. Therefore, we investigated LMPTP expression in
failing hearts from patients in end-stage heart failure
and in control hearts from subjects who suffered an
unexpected accidental death. Failing hearts displayed
compromised left ventricular (LV) function, with ejec-
tion fraction and fractional shortening below normal
values (averaging 20% and 10%, respectively). LMPTP
protein was significantly increased in failing human
hearts compared with control hearts (Figures 1E and
1F). This was associated with enhanced fibrosis, which
was prominent in failing human hearts but not in control
hearts (Supplementary Figure 1C). Lmptp expression
was also higher in BALB/c mouse hearts 10 weeks
post-TAC compared with sham controls (Figures 1G
and 1H). This was associated with a significant increase
in LV volume at diastole and systole, an increase of
the LV mass over body weight ratio, and reduced ejec-
tion fraction and fractional shortening (Supplementary
Figure 1D). Similar results were obtained when we
analysed Lmptp expression after TAC in the C57BL/6
background (Supplementary Figure 2). We conclude
that Lmptp expression is high in mouse heart during
early embryonic development, decreases in the postnatal
and adult stages, and is induced in response to pressure
overload in humans and in mice.
Mice with Acp1 ablation do not have an overt
phenotype under basal conditions
To investigate the role of Lmptp in vivo, we generated
Lmptp KO mice by insertion of a gene trap in the Acp1
locus (Supplementary Figures 3A and 3B) [22]. Acp1−/−
mice expressed no Lmptp protein in the heart, whereas
Acp1+/− mice expressed half the levels of Acp1+/+ (Sup-
plementary Figure 3C). Lmptp expression was simi-
larly undetectable by immunoblotting in lysates of liver,
skeletal muscle, adipose tissue, and tails of Acp1−/−
mice (data not shown), showing that our gene-trapped
mouse functions as a global KO. We did not detect
expression of IF2p [11] in Acp1+/+ or Acp1−/− mice,
suggesting that IF2p is a true pseudogene (Supplemen-
tary Figure 3D). Acp1+/− and Acp−/− mice were born at
expected Mendelian ratios and developed normally. No
gross difference in body anatomy was observed between
Acp1+/+ and Acp−/− mice. Acp1−/− mice were slightly
smaller than Acp+/+ mice at week 10; however, the dif-
ference was not significant at later times of development
(Supplementary Figures 4A and 4B). Heart morphology
(Supplementary Figures 4C and 4D) and resting car-
diac function at 2 months (Supplementary Table 1) were
similar in Acp1+/+ and Acp−/− mice. Mouse weights, as
well as the weights of hearts, left and right atria, left
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Figure 1. Expression of Lmptp during embryonic and postnatal cardiac development and after pathological stress. (A) Immunoblot of
Lmptp in adult mouse heart. (B) Indirect immunofluorescence of adult mouse heart sections showing Lmptp expression in the sarcolemmal
membrane and lower expression in the cytosol. Signals were visualized by confocal microscopy using a 20× objective. (a) Lmptp expression;
(b) negative control; (c) higher magnification of a; (d) higher magnification of b. (C) Immunoblot showing the developmental time course
of Lmptp expression in mouse heart at embryonic days E11.5, E15, and E19, and at postnatal days 1 (P1) and 7 (P7) and at day 30. (D)
Quantitation of C. (E) LMPTP protein level in control and failing human hearts measured by immunoblot and (F) quantitative analysis
(n= 5). (G) Immunoblot of Lmptp in the hearts of wild-type (WT) mice subjected to sham operation or TAC for 10 weeks (n= 4) and (H)
quantitative analysis. p values are indicated (Student’s t-test).
and right ventricles, liver, and tibia lengths, were similar
in Acp1+/+ and Acp−/− mice (Supplementary Table 2).
Since Acp1-null mice have not been reported previously,
we performed a pathology survey of various tissues in
aged Acp1+/+ and Acp−/− mice. Internal organs includ-
ing the heart, brain, lungs, liver, kidney, small intes-
tine, pancreas, skin, and reproductive organs from 16- to
21-month-old male and female mice did not display any
obvious anatomical abnormalities or pathology (data
not shown). We conclude that Acp1−/− mice are viable
and fertile, do not develop spontaneous pathology, and
appear to have a normal cardiac phenotype at baseline.
Mice with Acp1 ablation have preserved cardiac
contractility, attenuated fibrosis, and reduced
up-regulation of heart failure markers after chronic
pressure overload
Since Acp1−/− mice did not show an overt pheno-
type under basal conditions, we investigated their
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Figure 2. Acp1−/− mice are resistant to pressure overload-induced hypertrophy and heart failure. Longitudinal assessment of ventricular
septum thickness and posterior wall thickness at systole (A, B), end-systolic volume and end-systolic diameter (C, D), ejection fraction (E),
and fractional shortening (F) measured by echocardiography over 10 weeks after sham operation or TAC in Acp1+/+ or Acp1−/− mice. *p <
0.05, **p < 0.01, ***p < 0.001, and ****p < 0.001 between Acp1+/+ TAC and Acp1−/− TAC animals. †p < 0.05, ††p < 0.01, †††p < 0.001, and
††††p < 0.001 between Acp1+/+ TAC and Acp1+/+ sham animals (n = 9, Acp1+/+ sham; n = 8, Acp1+/+ TAC; n = 10, Acp1−/− sham; n = 10,
Acp1−/− TAC). Statistical analysis was performed using ANOVA.
response to pressure overload hypertrophy induced by
constriction of the aorta (TAC). No significant changes
in LV dimension or cardiac function were observed in
Acp1+/+ and Acp−/− mice over 10 weeks after sham
operation (Figures 2A–2F). Acp1+/+ mice developed
cardiac hypertrophy between weeks 4 and 7 post-TAC,
as evidenced by increased interventricular septum
thickness (Figure 2A) and increased posterior wall
thickness (Figure 2B and Supplementary Figure 5A).
Starting at week 7, Acp1+/+ mice showed increased
systolic volume and end-systolic diameter after TAC
(Figures 2C and 2D), whereas end-diastolic diameter
was not significantly affected (Supplementary Figure
5B). Also, starting 7 weeks post-TAC, Acp1+/+ mice
had reduced ejection fraction and fractional shorten-
ing (23.4% and 14.16%, respectively) (Figures 2E
and 2F) indicative of severely compromised contrac-
tile function. In contrast, Acp−/− mice subjected to
TAC displayed no signs of cardiac hypertrophy, no
significant enlargement of the ventricular chambers
(Figures 2C, 2D, and Supplementary Figure 5A), and
no deterioration of haemodynamic function (Figures 2E
and 2F). TAC-induced increases in heart weight/body
weight (HW/BW) ratio were significantly attenuated in
Acp1−/− mice compared with Acp1+/+ after 10 weeks
(Figures 3A and 3B). Consistent with these results, cell
surface area as measured by wheat germ agglutinin
staining showed no difference between Acp1+/+ and
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Acp−/− hearts at baseline. In contrast, pressure overload
increased the cell surface area in Acp1+/+ hearts but not
in Acp1−/− hearts (Figures 3C and 3D). Cardiac fibrosis
was also markedly attenuated in Acp1−/− compared
with Acp1+/+ mice 10 weeks post-TAC (Figures 3E and
3F). Next, we measured fetal cardiac genes, which are
down-regulated after birth and re-expressed in cardiac
hypertrophy and heart failure. The results showed a sig-
nificant up-regulation of β-myosin heavy chain (β-Mhc)
and atrial natriuretic peptide (Anp) mRNA in the hearts
of Acp1+/+ mice after TAC. In contrast, Anp and
β-Mhc were not as strongly transcriptionally induced
in Acp1−/− banded hearts (Figure 3G). These results
show that ablation of Acp1 minimizes cardiac fibrosis
and the genetic re-programming of fetal cardiac genes
in response to long-term haemodynamic stress. Taken
together, these results show that Acp1 deletion prevents
the development of pathological cardiac hypertrophy
and heart failure.
Gene expression profiling in Acp1−/− mice after
chronic pressure overload
To gain insight into the mechanism of the improved
adaptation of Acp1−/− mice to pathological stress, we
performed genome-wide expression profiling inAcp1+/+
and Acp−/− hearts after 10 weeks of sham or TAC
surgery. Microarray data represented as a ‘heat map’
showed global expression similarities between Acp1+/+
and Acp−/− hearts after sham operation (Figure 4A; see
Supplementary Table 3 for a full list of the genes).
Conversely, widespread expression differences were
observed between Acp1+/+ sham hearts and Acp1+/+
TAC hearts (Figure 4A), with 828 differentially regu-
lated genes (Supplementary Figure 6B), among which
were heart failure marker genes such as Anp and β-Mhc,
and genes associated with fibrosis such as collagen type
α (Supplementary Table 4; see Supplementary Table 5
for the full microarray data). Pressure overload altered
the expression of 419 genes in Acp1−/− hearts compared
withAcp1+/+ hearts (Supplementary Figure 6B; see Sup-
plementary Table 6 for the full data). The DAVID func-
tional clustering tool that groups genes according to their
ontology (GO) [25,26] revealed that genes encoding
receptor and non-receptor tyrosine kinases were among
the most dysregulated (Supplementary Figure 7). Impor-
tantly, major diseases and functions to which these genes
belonged were cardiac hypertrophy, dilation, and fibro-
sis (Figure 4B). Among the hypertrophy-related genes,
Camk2δ was expressed at a higher level in Acp1+/+
TAC hearts than in Acp−/− TAC hearts, which was val-
idated by immunoblot analysis (Figures 4C and 4D).
Also, Gαq/11 and PLCδ protein expression, which pro-
motes pathological cardiac hypertrophy, was signifi-
cantly higher in Acp1+/+ TAC hearts than in Acp1−/−
TAC hearts (Figures 4C and 4D). Pro-apoptotic pro-
tein Bax was strongly induced in Acp1+/+ TAC hearts
but not in Acp1−/− TAC hearts, whereas anti-apoptotic
proteins Bcl2 and BclXL remained mostly unchanged
(Figures 4E and 4F). Together, these results suggest that
Acp1 deletion confers cardioprotection at least in part by
enhanced expression of receptor and non-receptor tyro-
sine kinases, blockade of the CaMKIIδ pathway, and
reduced apoptosis.
Mice with Acp1 deletion have enhanced IRβ
phosphorylation, PKA, ephrin receptor, and reduced
PLCβ/CaMKIIδ phosphorylation after short-term
pressure overload
Our transcriptional analysis suggested that increased
signalling through the insulin receptor (IR); increased
expression of PKA, NFκB, and ephrin receptor
(Figure 5A); and inhibition of CaMKIIδ may con-
fer cardioprotection in Acp1−/− mice after long-term
chronic stress (Figures 4B and 4C). To confirm that
these pathways are implicated in early cardioprotection,
we performed short-term TAC (10min and 24 h) and
assessed these signalling pathways in the four groups
of mice. Since Lmptp regulates IR phosphorylation in
the liver [21], we first measured IRβ phosphorylation.
IRβ phosphorylation increased in Acp1−/− hearts after
10min of TAC compared with Acp1+/+ TAC hearts,
with a further increase 24 h post-TAC (Figures 5B and
5C). PKA and ephrin receptor were also significantly
increased in Acp1−/− hearts after 10min of TAC and
this effect was augmented 24 h post-TAC (Figures 5D
and 5E). NFκB increased after 24 h of TAC in Acp1−/−
hearts; however, the difference did not reach statisti-
cal significance. Next, we assessed the Akt pathway
downstream of the IR [27], which has a protective role
in the heart. Unexpectedly, phosphorylation of Akt
increased in Acp1+/+ hearts after 24 h of TAC, with
no further increase in Acp1−/− TAC hearts (Supple-
mentary Figure 8). Assessment of the Erk and p38
pathways, which are also activated downstream of
the IR, showed similar levels of phosphorylation in
Acp1+/+ and Acp1−/− mice after 10min or 24 h of TAC,
suggesting that these pathways do not contribute to the
protective phenotype of Acp1−/− mice (Supplementary
Figure 8).
Since our transcriptional analysis showed reduced
CaMKIIδ expression in Acp1−/− hearts after chronic
stress, we assessed this pathway after short-term pres-
sure overload. Strikingly, Gαq/11 and phosphorylation
of PLCβ and CaMKIIδ, which have known deleterious
effects in the heart, were increased after short-term
pressure overload in Acp1+/+ hearts but not in Acp1−/−
hearts, indicating that CaMKIIδ inhibition likely pro-
vides protection in Acp1−/− hearts (Figures 6A and 6B).
Next, we assessedwhether deletion ofAcp1 is associated
with altered expression of calcium-regulated proteins.
Sarcoplasmic reticulum calcium ATPase (Serca2a)
mRNA did not change in Acp1−/− and Acp1+/+ hearts
after pressure overload (Supplementary Figure 8).
Phospholamban (Pln), which regulates Serca2a and
is phosphorylated by PKA and CaMKIIδ, was also
assessed in the four groups of animals. Pln mRNA
levels were increased in both Acp1+/+ and Acp−/− hearts
after TAC. However, the difference was not statistically
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 237: 482–494
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
488 F Wade et al
Figure 3. Acp1−/− mice are protected against fibrosis and heart failure. (A) Representative images of the hearts of Acp1+/+ and Acp−/− mice
after 10 weeks of sham or TAC. (B) Heart/body weight ratio in Acp1+/+ and Acp−/− mice after 10 weeks of sham or TAC surgery. Acp1+/+ sham
and Acp−/− sham n= 4, Acp1+/+ TAC n= 7, Acp1−/− TAC n= 4. (C) Wheat germ agglutinin staining in heart sections of Acp1+/+ and Acp1−/−
mice 10 weeks after sham or TAC surgery and (D) quantitative measurement of the cell surface area from 100 cells in three different fields
from three animals in each group of mice. (E) Masson’s trichrome staining of heart sections of Acp1+/+ and Acp1−/− mice 10 weeks after
sham or TAC surgery. (F) Significant reduction of cardiac fibrosis in Acp1−/− mice compared with Acp1+/+ mice after pressure overload, as
evidenced by quantification of the fibrotic area over the total area (n= 5). (G) qPCR analysis for β-Mhc, Anp, α-Mhc, and Gapdh in whole
heart lysates at 10 weeks post-sham or TAC (n= 3). p values are shown on each graph (Student’s t-test).
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 237: 482–494
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Figure 4. Microarray analysis of Acp1+/+ and Acp1−/− mouse hearts after sham or TAC surgery. (A) Heat map showing the clustering of
significantly dysregulated genes in Acp1−/− and Acp1+/+ mice after sham surgery (n= 2) or TAC (n= 5) (p< 0.01, 428 probes). Red colour
indicates genes significantly up-regulated, while green indicates genes significantly down-regulated. (B) Major diseases and functions
connected to genes dysregulated in Acp1+/+ TAC hearts compared with Acp1−/− TAC hearts. (C) Immunoblot of CaMKIIδ, Gαq/11, and PLC
protein expression in Acp1−/− TAC hearts compared with Acp1+/+ TAC hearts. (D) Quantitative analysis of C over GAPDH control (n= 3–5).
(E) Immunoblot of anti- and pro-apoptotic proteins in Acp1−/− TAC hearts compared with Acp+/+ TAC hearts. (F) Quantitative analysis of E
over GAPDH control (n= 3–5). Significant p values are shown (Student’s t-test).
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 237: 482–494
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Figure 5. Increased IR phosphorylation, PKA, and ephrin receptor expression in Acp1−/− hearts subjected to TAC compared with Acp1+/+
TAC hearts. (A) Ingenuity pathway analysis showing the most significantly increased canonical pathways in Acp1−/− TAC hearts compared
with Acp1+/+ TAC hearts after 10 weeks of TAC or sham surgery. (B) Immunoprecipitation from Acp1+/+ and Acp1−/− mouse hearts after
10min and 24 h of sham or TAC using anti-IRβ antibody followed by immunoblotting using anti-4G10 antibody. (C) Quantitation of B; n= 3
in each group of mice. (D) Immunoblot for PKA, NFκB, and ephrin receptor in Acp1+/+ and Acp1−/− mouse hearts after 10min and 24 h of
sham or TAC. (E) Quantitation of D from three animals in each group. p values between Acp1+/+ TAC and Acp1−/− TAC hearts after Student’s
t-test are shown.
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Figure 6. Reduced activation of CaMKIIδ and PLC pathways in Acp1−/−hearts subjected to TAC compared with Acp1+/+ TAC hearts. (A)
Immunoblot showing Gαq/11, total and phosphorylated CaMKIIδ, PLCβ, and PLB in Acp1+/+ or Acp1−/−mouse hearts after 10min and 24 h
of TAC or sham surgery. (B) Quantitative analysis of A from three animals in each group. p values obtained after Student’s t-test are shown.
significant. Immunoblot analysis showed that Pln was
mainly non-phosphorylated at baseline in Acp1+/+
hearts and its phosphorylated form increased after 24 h
of TAC. In contrast, total Pln was relatively low in
Acp1−/− hearts at baseline and after TAC, while phos-
phorylated Pln was high in Acp−/− hearts regardless of
the cardiac stress (Figures 6A and 6B). Together, these
data suggest that Acp1−/− mice are protected against
pathological stress due to alteration of several signalling
pathways, including activation of protective path-
ways (ie IRβ, PKA, ephrin receptor) and inhibition of
deleterious pathways such as CaMKIIδ/PLC signalling.
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Discussion
LMPTP is a small PTP that defines a separate class
of PTPs [6] whose function in heart muscle remains
unknown. In the present study, we generated mice with
global deletion of Lmptp (Acp1) and show that Lmptp
deficiency protects against pathological cardiac hyper-
trophy and cardiac dysfunction, and attenuates cardiac
fibrosis and apoptosis in response to long-term stress.
The protective mechanism involves limited genetic fetal
reprogramming, activation of receptors and molecules
with cardioprotective functions, and attenuation of
deleterious pathways.
Acp1-null mice showed normal heart development
and function, and no organ pathology under basal
conditions. Rather, deletion of Lmptp blocked car-
diac hypertrophy, significantly attenuated fibrosis,
and improved haemodynamic function in a pressure
overload model of heart failure. Cardiac hypertrophy
and heart failure are characterized by transcriptional
reprogramming of genes expressed during fetal car-
diac development, which are silenced after birth and
induced in pathological conditions. Reactivation of
fetal cardiac genes is considered a hallmark of cardiac
hypertophy and failure. Likewise, we evaluated fetal
genes in the four groups of mice. A strong induction
of β-MHC and ANF occurred in wild-type mice after
stress, while minimal expression was observed in
Acp1-null mice after pressure overload. These obser-
vations, together with the developmental regulation
of Lmptp and up-regulation of Lmptp in the adult
heart after pathological stress, suggest that mainte-
nance of the adult cardiac gene programme is a likely
proximal protective mechanism. However, the recent
report that pressure overload induces β-MHC expres-
sion in a restricted number of small non-hypertrophic
cardiomyocytes raises the intriguing possibility, yet
to be demonstrated, that fetal genes may be pro-
tective [28]. Whether reactivation of the fetal gene
programme has a protective or deleterious effect is
difficult to address, as this process involves complex
transcriptional, post-transcriptional, and epigenetic
alterations.
Several signalling pathways appear to be implicated
in the protective mechanism of Lmptp ablation. Our
transcriptional analysis showed increased expression of
IR-induced genes in Acp1−/−mice after long-term stress.
The IR is currently one of the most validated substrates
of the LMPTP, based on in vitro and in vivo studies
conducted using antisense oligonucleotides [16–20]. On
this basis, and since activation of physiological sig-
nalling pathways downstream of the IR is beneficial
in the setting of cardiac failure [29–31], we hypothe-
sized that activation of the IR/Akt pathway may con-
fer cardioprotection. Our molecular analysis performed
after short-term stress showed a strong increase in IRβ
phosphorylation in Acp1−/− mouse hearts, which was
not associated with enhanced Akt activity. These results
suggest that the IR/Akt pathway is not the primary
pathway conferring cardioprotection after pathological
cardiac stress. ERK and MAPK pathways are known
to be activated by receptor tyrosine kinases. However,
our results showed similar levels of ERK and MAPK
activation in Acp1+/+ and Acp1−/− mice after sham and
short-term TAC. We attribute this unexpected obser-
vation to the BALB/c background of the mice. Relat-
edly, cardiac hypertrophy is usually a quick response
following pressure overload; however, cardiac hypertro-
phy was observed between weeks 4 and 7 post-TAC in
Acp1+/+ mice, suggesting a delayed response to haemo-
dynamic stress in BALB/c mice. PKA and ephrin recep-
tor expression was increased in Acp1−/− mice after stress
compared with Acp1+/+ TAC mice. Since there is evi-
dence of a protective role of these effectors in the heart
[32–35], it is conceivable that they account for part of
the cardioprotective effect of Lmptp deletion. Evalua-
tion of the downstream effectors of these molecules will
be required to ascertain their protective role in Acp1-
deficient hearts.
No activation of CaMKIIδ and PLCβ occurred in
Acp1−/− mice after short-term and prolonged pressure
overload. Since PLC and CaMKIIδ are important medi-
ators of pathological cardiac remodelling [36–40], it
is highly likely that the resistance of Acp1−/− mice
to pathological stress is mediated at least in part by
blockade of PLC/CaMKIIδ pathways and possibly
maintenance of calcium homeostasis. Serca2a mRNA
levels, however, remained similar under basal conditions
and after short-term TAC in Acp1+/+ and Acp1−/− mice.
Since cardiac hypertrophy and heart failure are known
to reduce Serca2a expression, our data suggest that the
calcium pump is not regulated by short-term stress.
Phosphorylated Pln, however, appeared to be higher in
Acp1-deficient hearts at baseline and remained high after
short-term stress, suggesting that maintenance of cal-
cium release from the sarcoplasmic reticulum is critical
to preserve cardiac contractility in Acp1-null mice.
In summary, our study reports for the first time that
Acp1 deletion in mice prevents cardiac hypertrophy,
fibrosis, ventricular chamber dilation, and cardiac
dysfunction associated with pathological cardiac
remodelling. Repression of the fetal cardiac gene pro-
gramme is a likely proximal event in the protective
mechanism, but additional mechanisms contribute to
the preserved phenotype caused by Acp1 deficiency. IR
phosphorylation, activation of PKA, ephrin
receptors, and inhibition of Gαq11/PLC/CaMKIIδ are
early responses following stress challenge, suggesting a
role for these pathways in the cardioprotective function
of Acp1 deletion. Detailed investigations of the effect
of Lmptp in isolated cardiac myocytes, as well as the
generation of models carrying conditional deletion of
Lmptp in cardiac muscle, will be critical to complete the
picture of the role of this phosphatase in the heart. Since
globalAcp1KOhas a benign phenotype, development of
LMPTP-targeted chemical inhibitors is warranted to fur-
ther assess its role in cardiac failure and validate LMPTP
as a possible target for therapy for cardiac diseases.
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